About Kathrin Jansen

A member of Pfizer’s Worldwide Research, Development, and Medical leadership team, Dr. Jansen leads a fully integrated, global vaccines research and development organization. Her responsibilities range from discovery to registration and post-marketing commitments and a clinical vaccines portfolio that includes vaccines to prevent or treat diseases of significant unmet medical need. These include Streptococcus pneumonia, Clostridium difficile, Respiratory syncytial virus, Group B streptococcus and prostate cancer. Dr. Jansen’s recent accomplishments are the global licensures of Prev(e)nar13® to prevent pneumococcal diseases and the development and licensure of Trumenba®, the first vaccine licensed in the United States to prevent invasive disease caused by Neisseria meningitidis serogroup B.

While at Merck Research Laboratories, Dr. Jansen initiated R&D activities and led the development of Gardasil®, the world’s first cervical cancer vaccine. She has authored and co-authored over 170 publications, and is member of the Coalition for Epidemic Preparedness Innovations (CEPI) scientific advisory committee, American Society for Microbiology and a Fellow of the Royal Society of Medicine. Dr. Jansen has over 25 years of pharmaceutical experience in vaccine research and development.